Patient satisfaction instruments for cancer clinical research or practice.

abstract：:Given growing interest in multicriteria decision making and multiple cost-effectiveness thresholds' approach, it was decided to investigate its usefulness in Poland. The pricing and reimbursement (P&R) regulations were reviewed and a cross-sectional survey was conducted amongst nurses. The study investigated whether P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kolasa K

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grewal S,Ramsey S,Balu S,Carlson JJ

更新日期：2018-08-01 00:00:00

abstract：AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Regnier SA,Alsop J,Wright J,Nixon R,Staines H,Fajnkuchen F

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wijnen BFM,Thielen FW,Konings S,Feenstra T,Van Der Gaag M,Veling W,De Haan L,Ising H,Hiligsmann M,Evers SMAA,Smit F,Lokkerbol J

更新日期：2020-06-01 00:00:00

abstract：INTRODUCTION:For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence to medications, losing many people who might benefit from treatment and exposing them to unnecessary ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wagg A

更新日期：2016-08-01 00:00:00

abstract：INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2019-04-01 00:00:00

abstract：OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cangelosi MJ,Ortendahl JD,Meckley LM,Bentley TG,Anene AM,Shriner KM,Fox J

更新日期：2015-04-01 00:00:00

abstract：AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Szmurło D,Fundament T,Ziobro M,Kruntorádová K,Doležal T,Głogowski C

更新日期：2014-06-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：:Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

更新日期：2010-10-01 00:00:00

abstract：:We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Neumann PJ,Saret CJ

更新日期：2013-10-01 00:00:00

abstract：:Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

更新日期：2011-04-01 00:00:00

abstract：:In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Diaby V,Goeree R

更新日期：2014-02-01 00:00:00

abstract：:In response to concerns about the cost burden of medical care in general and rising pharmaceutical costs in particular, a number of recent studies have examined trends in pharmaceutical expenditures. These studies have reached apparently disparate conclusions about factors responsible for rising pharmaceutical costs a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Crown WH,Ling D,Berndt E

更新日期：2002-10-01 00:00:00

abstract：:The past 10 years has witnessed a major transformation in the treatment of rheumatoid arthritis, a chronic condition that leads to significant morbidity, impairment in quality of life and mortality. Adalimumab joins a class of biologic response modifiers that prevent joint destruction and maintain functional status. F...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bansback N,Brennan A,Anis AH

更新日期：2005-10-01 00:00:00

abstract：:Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Embleton ND,Dharmaraj ST,Deshpande S

更新日期：2007-10-01 00:00:00

abstract：:It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feldman SR,Pearce DJ

更新日期：2004-10-01 00:00:00

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：:Most national guidelines for pharmacoeconomic research prescribe discounting, mostly of money and health against the same rate. There is much debate on whether this is adequate. Two theoretical arguments, the consistency argument of Weinstein and Stason, and the paralyzing paradox of Keeler and Cretin, are mostly resp...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Klock RM,Brouwer WB,Annemans LJ,Bos JM,Postma MJ

更新日期：2005-02-01 00:00:00

abstract：:Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2003-06-01 00:00:00

abstract：BACKGROUND:The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM:To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METH...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gimeno-Ballester V,Mar J,San Miguel R

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

更新日期：2018-04-01 00:00:00

abstract：:Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2009-08-01 00:00:00

abstract：:The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2014-04-01 00:00:00

abstract：:The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thicknes...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cormier JN,Xing Y,Ross MI,Cantor SB

更新日期：2004-12-01 00:00:00

abstract：BACKGROUND:In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-incom...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Vogler S,Zimmermann N,Babar ZU

更新日期：2017-04-01 00:00:00

abstract：:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuipers P,Foster MM,Bellamy N

更新日期：2003-04-01 00:00:00

abstract：:Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Breau LM

更新日期：2003-06-01 00:00:00

abstract：:This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Akincigil A,Wei W,Crystal S

更新日期：2005-06-01 00:00:00

abstract：:Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical tr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wade WE,Spruill WJ

更新日期：2007-06-01 00:00:00